Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid) is a selective agonist for HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) receptors, enabling targeted modulation of lipid metabolism in research settings (Ye et al., 2025). The compound’s purity (98%) and defined solubility parameters (<21.82 mg/ml in ethanol and DMSO) make it highly suitable for reproducible in vitro assays (APExBIO product page). Recent cryo-EM structures provide atomic-level insights into Acifran’s receptor selectivity, supporting rational experimental design. Acifran is not intended for diagnostic or medical use, and solutions require prompt utilization for maximal activity. This article extends prior guidance by integrating new structural findings and practical workflow recommendations for lipid signaling research.

Biological Rationale

Lipid metabolism is regulated by G-protein coupled receptors (GPCRs), notably HM74A/GPR109A (HCAR2) and GPR109B (HCAR3). These receptors are hydroxycarboxylic acid receptors involved in energy homeostasis and the modulation of circulating lipids (Ye et al., 2025). Acifran selectively targets both HCAR2 and HCAR3, enabling focused interrogation of lipid signaling pathways and metabolic disorder mechanisms (Related Article). Compared to endogenous ligands (e.g., niacin), Acifran provides improved selectivity and reduced off-target effects, which is essential for dissecting receptor-specific functions in metabolic research. This selectivity is particularly relevant for avoiding adverse responses linked to HCAR2 activation, such as cutaneous flushing (Ye et al., 2025).

Mechanism of Action of Acifran

Acifran acts as a hypolipidemic agent by binding to the orthosteric site of HM74A/GPR109A and GPR109B. Cryo-EM data reveal that Acifran occupies the ligand-binding pocket, engaging in π–π interactions with critical residues such as F1073.32 in HCAR3 and L1073.32 in HCAR2, which determine receptor selectivity (Ye et al., 2025). This interaction modulates downstream Gi protein signaling, resulting in decreased cAMP levels and altered lipid metabolism. The high affinity and selectivity of Acifran are attributed to its molecular fit within R1 and R2 regions of HCAR3’s binding pocket. This precise engagement underlies its utility in research on lipid signaling and metabolic disorders (Related Article—this article integrates recent cryo-EM findings not previously detailed).

Evidence & Benchmarks

• Acifran displays high binding affinity to both HCAR2 and HCAR3, with resolved cryo-EM structures at 2.72 Å (HCAR2) and 3.18 Å (HCAR3) resolution (Ye et al., 2025).
• Functional cAMP assays in HEK-293 cells confirm Acifran’s agonist activity and selectivity for both receptor subtypes (Ye et al., 2025).
• Acifran demonstrates minimal solubility above 21.82 mg/ml in ethanol and DMSO, aligning with vendor specifications for reliable assay design (APExBIO).
• Compounds structurally similar to Acifran exhibit lower selectivity or induce more adverse effects (e.g., cutaneous flushing), reinforcing Acifran’s research value (Ye et al., 2025).
• Atomic coordinates and cryo-EM density maps for Acifran-GPCR complexes are publicly available (PDB: 9JKX, 9JKY; EMDB: EMD-61573, EMD-61574) for benchmarking and computational studies (Ye et al., 2025, Supporting Data).

Applications, Limits & Misconceptions

Acifran is designed for scientific research on lipid metabolism, GPCR signaling, and metabolic disorder models. Its selectivity and purity improve assay reproducibility and mechanistic clarity, essential for hypothesis-driven lipid signaling studies. The Acifran B6848 kit enables targeted receptor activation without the confounding side effects of less selective agonists. Applications include cell viability, proliferation, cytotoxicity assays, and pathway interrogation (Related Article—this article updates with new structural validation for selectivity).

Common Pitfalls or Misconceptions

• Acifran is not intended for therapeutic or diagnostic use; its application is restricted to in vitro/in vivo research settings (APExBIO).
• Long-term storage of Acifran solutions leads to loss of activity; always prepare fresh aliquots as needed.
• Using concentrations above solubility limits (>21.82 mg/ml in ethanol or DMSO) may result in precipitation and unreliable results.
• Activation of non-target GPCRs by Acifran is minimal but not zero; verify selectivity depending on experimental context.
• HCAR3 activation may differ in rodent versus human models due to species-specific sequence divergence; extrapolate findings with caution (Ye et al., 2025).

Workflow Integration & Parameters

For optimal use, Acifran (B6848) should be stored as an off-white solid at -20°C and shipped with blue ice to preserve integrity (APExBIO). Dissolve in ethanol or DMSO below 21.82 mg/ml for stock preparation. Use prepared solutions immediately to avoid degradation. In cell-based assays, titrate Acifran to match the sensitivity and dynamic range of the target GPCR. For reproducibility, document solvent, concentration, temperature, and time conditions precisely. Refer to PDB and EMDB entries for molecular modeling or computational docking (Ye et al., 2025). For context-aware protocol optimization and troubleshooting, see this practical guide, which this article extends by synthesizing updated structural and stability parameters.

Conclusion & Outlook

Acifran, offered by APExBIO, is a rigorously characterized research compound that advances lipid metabolism and GPCR signaling studies. Its selectivity for HM74A/GPR109A and GPR109B, verified by atomic-resolution structures and functional assays, underpins its value in mechanistic and translational research. By integrating recent structural insights and robust workflow parameters, researchers can maximize assay reproducibility and mechanistic clarity. For further reading on the evolution of Acifran’s application, see this review, which this article updates with explicit structural-evidence integration.